| Product Name | Vildagliptin |
|---|---|
| Description | Vildagliptin, also known as LAF237, is a potent and selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin inhibits the inactivation of glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) by DPP-IV, allowing GLP-1 and GIP to potentiate the secretion of insulin and suppress glucagon release in the pancreas. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity in type 2 diabetes. |
| Synonyms | LAF237 |
| Molecular Weight | 303.4 Da |
| Target | Dipeptidyl peptidase IV |
| Amino Acid Sequence | 1-[2-[(3-Hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2S-pyrrolidinecarbonitrile |
| Form | White solid |
| Purity | 98% by tlc |
| Cas Number | 274901-16-5 |
| Storage | Store desiccated, frozen and in the dark |
| References |
Villhauer et al (2003) 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med. Chem. 46(13) 2774 PMID: 12801240AhreÌn et al (2004) Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes. J. Clin. Endocrinol. Metab. 89(5) 2078 PMID: 15126524Wu et al (2015) Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism 64(2) 226 PMID: 25195070 Related areasAll small molecules >All dipeptidyl peptidase IV modulators >All diabetes research categories > |
| Supplier | Isca Biochemicals Limited |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
